Fidson Healthcare Plc has announced its intention to raise N21 billion through a rights issue to support the company’s growth plans, including expanding manufacturing capacity, driving product innovation, and increasing market penetration across new territories.
The company held a signing ceremony in Lagos on December 12, 2025, to initiate the formal launch of its highly anticipated Rights Issue, following receipt of the final regulatory approval from the Securities and Exchange Commission (SEC) and the Nigerian Exchange Limited (NGX).
This strategic capital raise aims to generate a gross sum of up to N21 billion, an injection vital to consolidating Fidson’s leadership in the industry, providing funds for increased production capacity and its aggressive pan-African expansion goals.
The Issue involves the offering of 600 million new ordinary shares of 50 kobo each, priced at N35.00 per share. The shares are offered to existing shareholders on a one-for-four basis, with one new Ordinary Share for every four Ordinary Shares held as of the close of business on November 12, 2025, which is the qualification date.
This Rights Issue, which builds on a history of strategic capital-raising initiatives, comes at a time when the company has demonstrated exceptional performance, underscoring the strong operational execution and robust market position Fidson commands within the Nigerian and West African pharmaceutical landscape.
The N21 billion capital infusion is targeted explicitly at increasing manufacturing capacity, driving product innovation and expanding market penetration across new territories.
Speaking at the signing ceremony, the managing director/CEO of Fidson Healthcare, Biola Adebayo, stated that, “the successful formalisation of this N21 billion rights issue marks a critical milestone for Fidson. This capital will cement our position as the foremost healthcare company in Nigeria and a dominant player across Africa.
“Our exceptional performance this year has demonstrated our ability to thrive and innovate, and this successful offer assures us we can accelerate our growth trajectory and create sustainable, long-term value for all our stakeholders.”
The finance director, Imokha Ayebae highlighted the company’s impressive milestones in the capital market and explained the financial necessity and structure of the Issue.
“This Rights Issue has been meticulously structured to be financially compelling and viable for our loyal investors. The proceeds will be deployed judiciously to optimise our operations, including technology upgrades and expansion of our product lines. Eligible shareholders are strongly encouraged to exercise their provisional rights during the period, “he stressed.
The CEO of CardinalStone Partners Limited, Michael Nzewi said, he lead issuing house for the rights issue spoke about the equity capital raising journey of the company and indicated that, its last offering in 2019 was at N4.50 compared to the current offer price of N35 which is a discount to current market price is a testament to the growth trajectory of the Company’s stock and the attractiveness of holding Fidson shares in an investment portfolio.
